EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)

/in

OSLO/LONDON, 22 December 2021: Christmas came early at EXACT Therapeutics AS (“EXACT-Tx”, or “the Company”, Euronext Growth: EXTX) as the clinical-stage precision health company developing the proprietary ultrasound-mediated drug delivery platform Acoustic Cluster Therapy (ACT®) for use across multiple diseases, announces today that allowability has been found for its patent application in Europe (publication no. EP3049117) for its innovative Acoustic Cluster […]

Read more

Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes

/in

COPENHAGEN, DENMARK — Novo Holdings, a leading international life sciences investor, today announced a significant investment in 21st.BIO A/S – a new Danish bioindustrial scale-up company. Established in 2020, 21st.BIO has been founded with a mission to support bioindustrial companies globally in upscaling from molecule innovation to large-scale production to be able to meet market […]

Read more

EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®

/in

OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx” or “the Company”, Euronext Growth: EXTX), a clinical-stage precision health company developing the Acoustic Cluster Therapy (ACT®), a proprietary ultrasound-mediated drug delivery platform to enhance the efficacy of therapies across multiple diseases, today announces the award of a research and innovation grant from the Norwegian Research […]

Read more

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

/in

Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases Merck to accelerate development of Chord’s innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD) ‍Focused expansion in neuroinflammatory diseases builds on Merck’s existing neurology portfolio in Multiple Sclerosis (MS)  Geneva, December […]

Read more

Futura provides US regulatory and commercial update for MED3000

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, is pleased to provide an update on good progress with its regulatory and commercial activities for MED3000. MED3000 is the Company’s breakthrough, topical gel formulation for treatment of erectile dysfunction (“ED”).  It has the potential […]

Read more